000			02068nam a22001577a 4500
082			_a610
100			_aIqbal, Zarqa _9120002
245			_aEffect of Etoposide loaded Nanoparticles in the Treatment of Advanced Liver Diseases / _cZarqa Iqbal
264			_aIslamabad : _bSMME- NUST; _c2023.
300			_a76p. _bSoft Copy _c30cm
500			_aAdvanced liver diseases (ALD) continue to pose significant health challenges due to their high global prevalence and limited currently available curative options, besides liver transplantation. Liver disease therapeutics include many substances that may have insufficient effectiveness and severe adverse effects, such as Etoposide, having toxic nature with low compatibility and solubility in an aqueous solution. Nanoparticle-based therapeutics emerged as an efficient and safe treatment option to minimize side effects. Etoposide used for ALD is more toxic with low biocompatibility and solubility in an aqueous solution which makes it less efficient. The purpose of the study is to use nanoparticle-based etoposide for the treatment of ALD by improving its biocompatibility and solubility which makes this target-based therapy less toxic and more effective. Rat models used in this study were introduced with CCL4 and Urethane co-administration to develop liver cirrhosis. The thin film hydration method was used to synthesize etoposideencapsulated liposomal nanoparticles. The stability and stealth effect of liposomes were enhanced by polyethylene glycol (PEG) coating. Etoposides and PEG-coated etoposide liposomes were administered intravenously, into diseased rats. Results showed that etoposide and PEG-coated liposomal encapsulation are highly effective as compared to etoposide alone and blank nanoparticles and hence, be a substantial strategy for the treatment of ALD through intravenous drug delivery system.
650			_aMS Biomedical Sciences (BMS)
700			_aSupervisor : Dr. Nosheen Fatima Rana
856			_uhttp://10.250.8.41:8080/xmlui/handle/123456789/32405
942			_2ddc _cTHE
999			_c607470 _d607470